Optimality Considerations in Two-Stage Biomarker-Stratified Trials With Adaptive Enrichment.

We consider biomarker-stratified trials that test the treatment effect in a targeted patient group, the biomarker positive subgroup, and in the overall population. If the biomarker negative subgroup is stopped for futility during the interim analysis…

Preview only. Read the full abstract at the source